<DOC>
	<DOCNO>NCT01946399</DOCNO>
	<brief_summary>To determine Ozurdex implant offer effective treatment macular edema associate retinal vein occlusion treatment intravitreal Avastin , Lucentis , Eylea demonstrate significant response .</brief_summary>
	<brief_title>Ozurdex Implant Macular Edema After Treatment Failure With Anti-VEGF</brief_title>
	<detailed_description>To determine whether Ozurdex implant offer efficacious alternative treatment macular edema set retinal vein occlusion treatment intravitreal bevacizumab ( Avastin ) , ranibizumab ( Lucentis ) , and/or aflibercept ( Eylea ) demonstrate significant response .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>All patient Retinal Vein Occlusion ( RVO ) available initial imaging document treatment failure bevacizumab , ranibizumab , aflibercept . Treatment failure define lack anatomic improvement ( persistent intraretinal cystic changes/macular edema central subfield thickness great 250 micron timedomain OCT great 275 micron spectral domain OCT ) lack visual improvement ( le 2 line visual gain Snellen acuity ) , despite 3 6 intravitreal antiVEGF treatment precede 6 month . Coexisting preexist macular degeneration , diabetic macular edema , confound disease process Interval surgical intervention , cataract surgery , may confound visual outcome . Pregnancy Coexisting condition would represent relative absolute contraindication usage ozurdex implant , include : Ocular periocular infection ( include viral disease cornea conjunctiva active epithelial herpes simplex keratitis , vaccinia , varicella , mycobacterial infection , fungal disease ) Advanced glaucoma Aphakic eye rupture miss posterior lens capsule Eyes anterior chamber intraocular lens miss posterior lens capsule Patients know hypersensitivity component product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>